Novo Nordisk Pharmatech and Novozymes collaborate to manufacture specialty enzymes

DENMARK – Novozymes and Novo Nordisk Pharmatech have announced a collaboration agreement that brings together the companies’ shared competencies and interests in the development of specialty enzymes for use in biopharma processing and regenerative medicines. Enzymes used in biopharmaceutical processing currently account for a small portion of the Danish kr15 billion (US$2.27 billion) market for specialty enzymes, with annual growth rates in the high single digits expected. Older manufacturing technologies are increasingly being replaced by enzymatic alternatives, which is especially noticeable in regenerative medicines, which also require high quality, pharmaceutical…

Read More

Codexis completes its license transfer of its codeevolver technology to Novartis for non-exclusive use

US – Codexis, a leading enzyme engineering company enabling the promise of synthetic biology, has completed the transfer of its CodeEvolver platform technology with Novartis. The transfer comes two years later after both companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver to develop novel performance enzymes for use in the manufacture of pharmaceutical products. This licensing move will become the third of its kind and will have Novartis use it within its facility compared to the previous ones that had…

Read More

Codexis receives milestone payment from GlaxoSmithKline as it focuses on commercializing its CodeEvolver technology

WORLD – Codexis, a leading enzyme engineering company, has received a huge sum of money from GlaxoSmithKline (GSK), a drug manufacturing giant, in a deal that will provide GSK licensing rights to utilize the CodeEvolver technology. This milestone earning marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second…

Read More